Ribonucleotide reductase subunit M2 mRNA expression in pretreatment biopsies obtained from unresectable pancreatic carcinomas (Q44023706)

29 November 2017

Ribonucleotide reductase subunit M2 mRNA expression in pretreatment biopsies obtained from unresectable pancreatic carcinomas (English)

1 reference

29 November 2017

0 references

3

Noriyoshi Fukushima

1 reference

29 November 2017

Takao Itoi

1

1 reference

29 November 2017

Atsushi Sofuni

2

1 reference

29 November 2017

Fumihide Itokawa

4

1 reference

29 November 2017

Takayoshi Tsuchiya

5

1 reference

29 November 2017

Toshio Kurihara

6

1 reference

29 November 2017

Fuminori Moriyasu

7

1 reference

29 November 2017

Akihiko Tsuchida

8

1 reference

29 November 2017

Kazuhiko Kasuya

9

1 reference

29 November 2017

25 May 2007

1 reference

Journal of Gastroenterology

29 November 2017

1 reference

29 November 2017

42

1 reference

29 November 2017

389-394

1 reference

29 November 2017

5

1 reference

Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2-difluorodeoxycytidine in the human KB cancer cell line

29 November 2017

1 reference

12 December 2020

Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate

1 reference

12 December 2020

Phase II trial of gemcitabine, epirubicin and granulocyte colony-stimulating factor in patients with advanced pancreatic adenocarcinoma

1 reference

12 December 2020

Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer

1 reference

12 December 2020

The clinical utility of endoscopic ultrasound-guided fine-needle aspiration in the diagnosis and staging of pancreatic carcinoma

1 reference

12 December 2020

Triapine (3-aminopyridine-2-carboxaldehyde- thiosemicarbazone): A potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity.

1 reference

12 December 2020

RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer

1 reference

12 December 2020

Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer

1 reference

12 December 2020

Ribonucleotide reductase in cultured mouse lymphoma cells. Cell cycle-dependent variation in the activity of subunit protein M2

1 reference

12 December 2020

Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients

1 reference

12 December 2020

Phase I and pharmacokinetic study of the ribonucleotide reductase inhibitor, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, administered by 96-hour intravenous continuous infusion

1 reference

12 December 2020

Immunohistochemical analysis of p53 and MIB-1 in tissue specimens obtained from endoscopic ultrasonography-guided fine needle aspiration biopsy for the diagnosis of solid pancreatic masses

1 reference

12 December 2020

Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer

1 reference

12 December 2020

Endosonography-guided fine-needle aspiration biopsy: diagnostic accuracy and complication assessment

1 reference

12 December 2020

Quantitative analysis of K-ras gene mutation in pancreatic tissue obtained by endoscopic ultrasonography-guided fine needle aspiration: clinical utility for diagnosis of pancreatic tumor

1 reference

12 December 2020

An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma

1 reference

12 December 2020

A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer

1 reference

12 December 2020

Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer

1 reference

12 December 2020

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

12 December 2020

RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine

1 reference

12 December 2020

Cancer statistics, 2001

1 reference

12 December 2020

10.1007/S00535-007-2017-0

Identifiers

DOI

1 reference

29 November 2017

1 reference